Before the treatment of HIV infection with abacavir, patients have to undergo genetic screening for the HLA-B*5701 variant as this genotype is associated with a high incidence of severe cutaneous adverse drug reactions. This evidence concerns the gene HLA-B and HIV infectious disease.